Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients by unknown
LETTER Open Access
Optimal doses of caspofungin during
continuous venovenous hemodiafiltration
in critically ill patients
Gerardo Aguilar1* , Rafael Ferriols2, Angels Lozano1, Carlos Ezquer3, José A. Carbonell1, Ana Jurado1, Juan Carrizo1,
Ferran Serralta1, Jaume Puig1, David Navarro4,5, Manuel Alos2 and F. Javier Belda1,5
Keywords: Echinocandins, Continuous renal replacement therapy, Invasive candidiasis
The aim of the present study was to describe the
pharmacokinetics of caspofungin in 12 critically ill adult
patients with suspected or proven invasive candidiasis
who were receiving continuous venovenous hemodiafil-
tration (CVVHD).
CVVHD was performed using a polysulfone hemofilter
(Fresenius, Germany). Caspofungin was administered at
usual doses. Pre-filter and post-filter blood, ultradiafil-
trate, and urine samples were collected at steady state
on day 3 or later, before the dose infusion started, and
0.5, 1, 1.5, 2, 4, 6, 8, and 24 h after the infusion ended.
The drug concentrations were measured by high per-
formance liquid chromatograpy (HPLC) and the following
pharmacokinetic parameters were calculated: area under
the concentration-time curve (AUC0-24h), elimination t1/2,
volume of distribution (Vd), clearance, trough concentra-
tion (Ctrough), and maximum concentration (Cmax).
The results of our study are summarized in Tables 1
and 2 and Fig. 1. Caspofungin was negligible in the
ultradiafiltrate and urine samples, confirming the lack of
drug elimination through hemofiltration or hemodialysis.
Similar findings were previously described by Weiler et
al. [1]. Additionally, the mean concentration of caspo-
fungin was slightly higher in the post-filter line than in
the pre-filter line (Fig. 1), allowing us to rule out the
adsorption to the filter hypothesized in other studies
with echinocandins [2, 3].
In four patients (33%), the trough concentration of
caspofungin was lower than the MIC90s published for
Candida and Aspergillus spp., including Candida parapsi-
losis (2 mg/L) [4]. On the other hand, among echinocan-
dins, micafungin has been associated with 1 log kill/24 h
in a murine model of disseminated candidiasis when an
AUC/MIC of 865, 450, or 1185 is achieved for Candida
albicans, Candida glabrata, or C. parapsilosis, respectively
[5]. Taking into account a MIC of 0.1 mg/L [4], and
using the target pharmacokinetics/pharmacodynamics
(PK/PD) described for micafungin, we would have
reached this concentration in only nine patients (75%,
AUC > 86.5 mg h/L) for C. albicans and four patients
(33%, AUC > 118.5 mg h/L) for C. parapsilosis but all pa-
tients for C. glabrata (AUC > 45 mg h/L) (Table 2). These
data suggest that caspofungin dosing could be insufficient
in some critically ill patients.
In conclusion, CVVHD appears to have a negligible ef-
fect on caspofungin clearance. However, the licensed
regimen of caspofungin was not adequate to reach the
PK/PD targets in some critically ill patients, regardless
of the use of CVVHD. Nevertheless, future studies are
needed to confirm these findings.
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Table 1 Individual arterial caspofungin concentrations (mg/L) of the 12 patients studied
Time (h) 1 2 3 4 5 6 7 8 9 10 11 12
Predose 3.09 2.12 2.94 0.90 1.50 3.04 2.10 2.93 2.18 3.16 2.69 2.62
0.5 10.85 6.96 8.50 4.38 4.59 9.86 7.09 8.23 7.81 11.17 10.24 7.02
1 9.34 6.19 8.23 2.80 4.44 9.11 6.10 7.23 6.69 9.91 8.88 5.78
1.5 8.55 5.75 7.05 NA 4.41 8.24 5.27 6.04 6.03 8.42 8.39 5.09
2 7.51 5.47 6.91 2.43 3.85 7.37 4.96 5.88 5.72 7.74 7.92 4.61
4 6.38 4.49 6.13 2.12 3.77 6.54 4.13 5.66 5.32 6.94 6.62 3.94
6 5.63 3.96 5.63 NA 3.04 5.84 3.54 5.33 4.55 6.40 6.31 3.60
8 5.00 3.40 5.22 1.99 2.80 4.71 3.10 4.45 4.49 5.61 6.00 3.27
24 3.47 2.30 3.10 1.34 1.59 2.47 1.63 2.73 2.27 2.88 4.00 1.85
Time refers to the time since caspofungin infusion ended. NA data not available
Table 2 Pharmacokinetics of caspofungin during continuous venovenous hemodiafiltration in 12 patients
AUC0-24 (mg h/L)
Patient Arterial Venous Difference venous
to arterial (%)
Vd (L) Cl (L/h) Cmax (mg/L) Ctrough (mg/L) t½ (h)
1 140.0 180.0 29 14.1 0.356 12.5 3.47 27.4
2 88.3 106.0 20 17.1 0.567 7.8 2.1 21.0
3 124.0 152.0 23 10.9 0.402 8.8 3.1 18.8
4 65.4 77.4 18 26.8 0.765 6.9 1.3 24.3
5 68.0 90.0 32 17.5 0.735 4.8 1.5 16.5
6 102.0 107.0 5 13.6 0.683 10.7 2.5 13.8
7 65.6 78.8 20 15.0 0.762 8.3 1.6 13.6
8 100.0 113.0 13 13.9 0.499 9.5 2.7 19.3
9 102.0 127.0 25 14.1 0.685 9.2 2.3 14.3
10 121.0 142.0 17 12.5 0.578 12.6 2.9 15.0
11 190.0 224.0 18 13.9 0.368 11.5 4.0 26.2
12 60.1 74.5 24 27.7 1.165 8.5 1.9 16.5
Mean ± SD 102 ± 46 123 ± 46 20.3 ± 7.2 16.4 ± 5.4 0.630 ± 0.225 9.3 ± 2.3 2.4 ± 0.8 18.9 ± 4.9
SD standard deviation
Fig. 1 Average caspofungin concentration over time. Infusion started at 0 h and continued over 1 h. n = 12 patients. Solid dots, arterial; asterisks,
venous. (The figure is original for this article)
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